Anzeige
Mehr »
Login
Dienstag, 14.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Das 13-Millionen-Unternehmen mit einer Monster-Entdeckung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0HF9Y | ISIN: GB00B0H2K534 | Ticker-Symbol: P2F
Tradegate
14.01.25
14:17 Uhr
0,090 Euro
+0,008
+9,14 %
Branche
Öl/Gas
Aktienmarkt
Sonstige
1-Jahres-Chart
PETROFAC LIMITED Chart 1 Jahr
5-Tage-Chart
PETROFAC LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
0,0830,08816:29
0,0820,08816:24
Dow Jones News
327 Leser
Artikel bewerten:
(2)

Petrofac Limited: Board Update

Finanznachrichten News

DJ Petrofac Limited: Board Update

Petrofac Limited ( PFC) 
Petrofac Limited: Board Update 
07-Jan-2025 / 14:59 GMT/BST 
=---------------------------------------------------------------------------------------------------------------------- 
BOARD UPDATE 
Petrofac announces today that Non-executive Director Sara Akbar has notified the Board of her intention to step down 
from her duties to pursue other business interests. She will do so from 31 January 2025. 
 
Commenting, Petrofac Chair René Médori, said: 
"With significant experience of the Group's core Middle East region and energy sector, Sara has been a valuable 
contributor since joining the Petrofac Board in 2018. I would like to thank her for her commitment throughout her 
tenure, but particularly for her determination, alongside the wider Board, to deliver her fiduciary responsibilities 
during our recent strategic and financial review. This culminated in the announcement of a comprehensive financial 
restructuring in December, the completion of which will mark a new beginning for Petrofac." 
Sara Akbar said: 
"It has been a privilege to have spent six years with the Petrofac Board. The agreement of a lock up agreement in 
respect of the Group's financial restructuring represents an important milestone and I look forward to supporting the 
next stage of its implementation over the coming weeks, and seeing Petrofac emerge with the right foundations to 
deliver on its considerable potential. I will remain an ardent champion of this fantastic business and its global team 
as they begin a new chapter of growth." 
As a result of the Board changes announced today, the Directors now sit on the following Board Committees as follows: 
 
Nominations Committee: René Médori (Chair), Matthias Bichsel, David Davies 
Audit Committee: David Davies (Chair), Matthias Bichsel, Aidan de Brunner 
Compliance & Ethics Committee: Mattias Bichsel (Chair), David Davies, René Médori 
Remuneration Committee: Matthias Bichsel (Chair), David Davies, René Médori 
Special Committee: Aidan de Brunner (Chair), Tareq Kawash, Afonso Reis e Sousa 
The attention of stakeholders is drawn to the Company's announcement dated 22 December 2024, which detailed future 
changes to Petrofac's Board composition aligned with the aims of the Group's financial restructuring. 
ENDS 
 
For further information contact: 
 
Petrofac: 
James Boothroyd, Head of Investor Relations 
James.boothroyd@petrofac.com 
Sophie Reid, Group Director of Communications and Culture 
Sophie.reid@petrofac.com 
Teneo (for Petrofac): 
+44 (0) 207 353 4200 
petrofac@teneo.com 
 
NOTES TO EDITORS 
Petrofac 
Petrofac is a leading international service provider to the energy industry, with a diverse client portfolio including 
many of the world's leading energy companies. 
Petrofac designs, builds, manages and maintains oil, gas, refining, petrochemicals and renewable energy infrastructure. 
Our purpose is to enable our clients to meet the world's evolving energy needs. Our four values - driven, agile, 
respectful and open - are at the heart of everything we do. 
Petrofac's core markets are in the Middle East and North Africa (MENA) region and the UK North Sea, where we have built 
a long and successful track record of safe, reliable and innovative execution, underpinned by a cost effective and 
local delivery model with a strong focus on in-country value. We operate in several other significant markets, 
including India, South East Asia and the United States. We have 8,500 employees based across 31 offices globally. 
 
Petrofac is quoted on the London Stock Exchange (symbol: PFC). 
 
=---------------------------------------------------------------------------------------------------------------------- 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
ISIN:      GB00B0H2K534 
Category Code: BOA 
TIDM:      PFC 
LEI Code:    2138004624W8CKCSJ177 
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State 
Sequence No.:  369122 
EQS News ID:  2063009 
 
End of Announcement EQS News Service 
=------------------------------------------------------------------------------------
 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2063009&application_name=news&site_id=dow_jones%7e%7e%7ef1066a31-ca00-4e1a-b0a4-374bd7d0face

(END) Dow Jones Newswires

January 07, 2025 09:59 ET (14:59 GMT)

© 2025 Dow Jones News
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.